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Background: Pulmonary Langerhans cell histiocytosis (PLCH) is a rare disorder characterised by granulomatous
proliferation of CD1a-positive histiocytes forming granulomas within lung parenchyma, in strong association with
tobacco smoking, and which may result in chronic respiratory failure. Smoking cessation is considered to be
critical in management, but has variable effects on outcome. No drug therapy has been validated. Cladribine
(chlorodeoxyadenosine, 2-CDA) down-regulates histiocyte proliferation and has been successful in curbing
multi-system Langerhans cell histiocytosis and isolated PLCH.
Methods and patients: We retrospectively studied 5 patients (aged 37–55 years, 3 females) with PLCH who
received 3 to 4 courses of cladribine therapy as a single agent (0.1 mg/kg per day for 5 consecutive days at
monthly intervals). One patient was treated twice because of relapse at 1 year. Progressive pulmonary disease with
obstructive ventilatory pattern despite smoking cessation and/or corticosteroid therapy were indications for
treatment. Patients were administered oral trimethoprim/sulfamethoxazole and valaciclovir to prevent opportunistic
infections. They gave written consent to receive off-label cladribine in the absence of validated treatment.
Results: Functional class dyspnea improved with cladribine therapy in 4 out of 5 cases, and forced expiratory
volume in 1 second (FEV1) increased in all cases by a mean of 387 ml (100–920 ml), contrasting with a steady
decline prior to treatment. Chest high-resolution computed tomography (HRCT) features improved with cladribine
therapy in 4 patients. Hemodynamic improvement was observed in 1 patient with pre-capillary pulmonary
hypertension. The results suggested a greater treatment effect in subjects with nodular lung lesions and/or
thick-walled cysts on chest HRCT, with diffuse hypermetabolism of lung lesions on positron emission tomography
(PET)-scan, and with progressive disease despite smoking cessation. Infectious pneumonia developed in 1 patient,
with later grade 4 neutrocytopenia but without infection.
Discussion: Data interpretation was limited by the retrospective, uncontrolled study design and small sample size.
Conclusion: Cladribine as a single agent may be effective therapy in patients with progressive PLCH.
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ticularly the pituitary gland with diabetes insipidus. In
contrast to multi-system LCH, LCH limited to the lungs
or pulmonary LCH (PLCH) is strongly associated with to-
bacco smoking, with more than 90% of patients who are
current or former smokers versus less than 50% in multi-
system LCH [1,2]. Langerhans cell proliferation in the
lungs culminates in bronchiolocentric granulomas, which
may cavitate into inflammatory, thick-walled cysts. Lung
lesions predominate in the upper lobes with relative sparing
of the bases. With disease progression, PLCH may evolve
into cicatricial, fibrotic, thin-walled cysts, with irreversiblel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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frequent, severe pulmonary hypertension (PH). Mutually-
exclusive mutations of BRAF (V600E) [3], MAP2K1 [4], and
ARAF [5] have been identified in more than half of cases,
likely contributing to clonal proliferation of Langerhans
cells or precursor cells [6]. However, the potential role of
corresponding inhibitors in PLCH is not known.
Smoking cessation, considered critical in PLCH man-
agement, may be followed by disease remission [7,8],
although the relationship between smoking cessation
and disease improvement remains unclear. PLCH recur-
rence, despite smoking cessation, has been reported [9].
Corticosteroids have often been given as first-line therapy
in progressive PLCH, especially with prominent nodules
on imaging, but without controlled proof of efficacy [10].
Cladribine or chlorodeoxyadenosine (2-CDA), a purine
nucleoside analog that is directly toxic to monocytes [11],
has been used successfully in multi-system LCH [12-15].
It has been reported to induce remission or improve lung
disease in several adults with PLCH [16-19], and is
currently being evaluated in prospective clinical trials
(www.clinicaltrials.gov, NCT01473797). However, placebo-
controlled trials are difficult to conduct in patients with
progressive disease and severe dyspnoea. Here, we report
on our single-centre experience with 5 adult patients who
received cladribine therapy for progressive, symptomatic
PLCH with lung function impairment.
Methods
Study population
This retrospective study was conducted in a tertiary
centre with expertise in rare lung diseases. The diagnosis
of PLCH was based on the following criteria: appropriate
clinical presentation with a typical, high-resolution com-
puted tomography (HRCT) pattern of nodules and/or
cysts, relatively sparing the lung bases; or compatible
clinical and imaging, and PLCH on video-assisted thora-
coscopic lung biopsy. Genetic analysis of BRAF V600E
mutation was performed in cases with available biopsy
samples. The first course of treatment in patient 2 has
been reported previously [16].
Cladribine therapy
All patients received oral and written information regard-
ing off-label cladribine given as “rescue therapy”, and their
written consent was obtained in all cases prior to treat-
ment initiation. Although treatment was not conducted in
the setting of a clinical trial, and because it was prescribed
off-label, particular care was taken to follow a pre-defined
treatment dose and design, and to capture all potential ad-
verse events and drug reactions. Patients were advised not
to smoke at visits. Cladribine was prescribed as a single
agent in all cases, especially without concomitant corti-
costeroid therapy or vinblastine. Treatment consisted of 3(or 4) courses, each with 0.1 mg/kg per day of subcutane-
ous cladribine for 5 consecutive days at monthly intervals.
It was administered intravenously in 1 case (patient 2).
Oral trimethoprim/sulfamethoxazole (cotrimoxazole, 400/
80 mg per day) and valaciclovir (500 mg twice a day) were
systematically prescribed until 6 months after the end of
cladribine therapy to prevent opportunistic infections.Investigations
In all patients, the following data were obtained to
evaluate individual responses to therapy and benefit:tol-
erance as part of off-label treatment, before and 1 to
3 months after the last course of cladribine: smoking
habits, World Health Organization (WHO) dyspnoea
functional class, fever, weight loss, adverse events, prior
and concomitant drug therapy, serum C-reactive protein
(CRP) level, arterial blood gases, pulmonary function
tests, including spirometry, plethysmography and low-dose
HRCT. Transthoracic echocardiography was performed
systematically before treatment initiation to screen for PH.
Right heart catheterisation was undertaken in cases of
suspected pre-capillary PH on echocardiography, e.g., with
estimated systolic pulmonary artery pressure of 35 mmHg
or greater. Selected cases were submitted to exploratory
positron emission tomography (PET).
Institutional Review Board approval is not required for
retrospective observational studies in France.Results
Findings common to all 5 patients
Five patients were treated, including 1 who received
therapy twice because of PLCH relapse occurring
12 months after the last cladribine dose. The diagnosis
was obtained by lung biopsy in 3 cases, and by clinical
and imaging criteria in the 2 other patients in whom
lung biopsy was declined due to PH (patient 1) or severe
lung function impairment (patient 5). BRAF V600E mu-
tation was present in patients 2 and 4, absent in patient
3, and no biopsy was performed in patients 1 and 5. On
imaging, a typical pattern of nodules and thick-walled
cysts was seen in patients 1, 2 and 3. Patient 4 presented
multiple nodules without cystic changes. A pattern with
predominant thin-walled cysts was apparent in patient 5.
Patient 2 was a never-smoker, whereas all the 4 others
had quit smoking. Patients 1 and 4 stopped smoking
3 months before cladribine initiation, but their lung
function continued to deteriorate despite smoking cessa-
tion (Figure 1). Patient 5 had quit smoking 3 years prior
to treatment. Patient 3 stopped smoking between the
second and third courses of cladribine. Two patients
(1 and 2) had received prednisolone without success





























Figure 1 Evolution of forced expiratory volume in 1 second (FEV1) before and after cladribine therapy in 5 patients. M-12: 12 months
before cladribine; M-6: 6 months before cladribine; Day 1 (cladribine): initiation of cladribine therapy; M + 6: 6 months after cladribine treatment.
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treatment in 4 cases, and forced expiratory volume in
1 second (FEV1) increased in all cases (Figure 1). Forced
vital capacity (FVC) recuperated with therapy by a mean
of 414 ml (0–1,000 ml), and FEV1 by a mean of 387 ml
(100–920 ml). Further pulmonary function tests and arter-
ial blood gases are reported in Table 1. Chest HRCT
features improved with cladribine therapy in 4 cases,
with regression in the number and size of nodules, and
decreased cyst wall thickness in all cases. Representative
examples of HRCT changes are shown in Figure 2. Pa-
tients were followed for 6–48 months (median: 22 months)
after cladribine therapy ended.
Individual observations
Patient 1: A 55-year-old man, current smoker, with a
history of 50 pack-years, presented in November 2010
with dyspnoea functional class III. Pulmonary func-
tion tests indicated an obstructive ventilatory pattern
with 16% diffusion capacity of carbon monoxide (DLco).
At echocardiography, estimated systolic pulmonary arter-
ial pressure was 86 mmHg. Right heart catheterisation
disclosed pre-capillary PH, with mean pulmonary ar-
terial pressure (mPAP) of 45 mmHg, pulmonary ar-
tery wedge pressure (PAWP) of 13 mmHg, cardiac index
of 3 l/min/m2, and pulmonary vascular resistance (PVR)
of 428 dyn.s−1.cm−5. Serum levels of NT-pro-brain natri-
uretic peptide and CRP were 417 pg/ml and 4 mg/l,
respectively. No significant hypermetabolism was seen
on PET-scan. PaO2 was 66 mmHg under 3 l/min nasal
oxygen, and long-term nasal supplemental oxygen was
initiated. The patient was advised to quit smoking, and
bosentan was started (62.5 mg, then 125 mg twice a day).
Four months later, despite decreased smoking, from
20 to 5 cigarettes per day, dyspnoea (functional class IV)and lung function worsened. Right heart catheterisa-
tion demonstrated hemodynamic improvement (mPAP:
45 mmHg, PAWP: 11 mmHg, PVR: 337 dyn.s−1.cm−5, car-
diac index: 4 l/min/m2). The patient definitively stopped
smoking. In April 2011, prednisolone (1 mg/kg per day)
was initiated, with gradual tapering to 0.5 mg/kg per day
over 3 months. In July 2011, lung function continued to
deteriorate, with further decrease in FEV1 of 200 ml.
Severe functional class IV dyspnoea persisted. Chest
HRCT revealed a typically-diffuse nodular pattern with
thin-walled cysts. Prednisolone was discontinued, and
cladribine was initiated. After 4 courses of subcutaneous
cladribine therapy with no significant adverse reactions,
dyspnoea, lung function, PaO2 (Table 1), and HRCT find-
ings (Figure 2) improved. Hemodynamic values rallied fur-
ther (mPAP: 40 mmHg, PAWP: 11 mmHg, PVR: 240 dyn.
s−1.cm−5, cardiac index: 4.87 l/min/m2). Unfortunately, the
patient resumed smoking 6 months after cladribine ther-
apy. PLCH relapsed, with increased dyspnoea and deteri-
oration of lung function.
Patient 2: A 37-year-old woman, non-smoker, was seen
in 2006 for dry cough, dyspnoea functional class II, fever,
night sweats, and weight loss. She had a medical history
of operated benign prolactinoma, with no sign of pituitary
LCH at histology. HRCT was typical for diffuse nodular
PLCH, which was confirmed by surgical lung biopsy. Pul-
monary function tests showed a restrictive pattern with
reduced DLco. CRP level was 45 mg/l. PET-scan disclosed
diffuse hypermetabolism of lung parenchyma. The patient
received prednisolone (0.5 mg/kg per day from October to
March 2007), with no change in clinical, functional, or
imaging manifestations. She then received 4 courses of
intravenous cladribine (from March to July 2008), which
was well tolerated. All symptoms had resolved 4 months
after treatment ended. CRP level was 1 mg/l. Lung function
Table 1 Patient characteristics before and after cladribine treatment
WHO functional class 6-MWD (m) FVC (l) ΔFVC (ml) FEV1 (l) ΔFEV1 (ml) FEV1/FVC (%) DLco (%) PaO2 (mmHg)
Cladribine Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post
Patient 1 M, 45 y IV III 60 220 2.67 (56%) 2.93 (62%) +260 1.00 (28%) 1.15 (32%) +150 38 37 15 16 60 (3 l) 65 (2 l)
Patient 2 F, 37 y II 0 NA NA 2.54 (66%) 3.54 (95%) +1,000 1.98 (61%) 2.90 (90%) +920 95 82 58 NA NA NA
Patient 2 F, 37 y relapse II 0 NA NA 3.33 (87%) 4.0 (110%) +670 2.43 (75%) 3.10 (95%) +670 72 79 52 70 NA NA
Patient 3 F, 55 y II-III I NA NA 2.88 (112%) 3.30 (126%) +420 1.96 (89%) 2.30 (104%) +340 69 71 67 62 82.5 NA
Patient 4 M, 50 y II II 495 NA 4.30 (98%) 4.43 (101%) +130 1.40 (41%) 1.61 (47%) +210 32 36 66 68 79.5 91.5
Patient 5 F, 40 y II-III II-III 267 282 2.6 (78%) 2.6 (79%) +0 0.8 (29%) 0.9 (31%) +100 29 18 30 28 82.5 84
NA: not available; 6-MWD: 6-minute walk distance; DLco: diffusing capacity of carbon monoxide, FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; Δ: variation of FVC and FEV1 before and after
cladribine treatment; PaO2: pulmonary arterial tension in blood gases, WHO: World Health Organization.





















Figure 2 Representative HRCT features before (A, C, E, G, I, K) and after cladribine therapy (B, D, F, H, J, L) in 3 patients. A, B: patient 1;
C, D: patient 2; E, F: patient 2 (relapse); G, H: patient 3.
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found on PET-scan. In July 2009, PLCH relapsed with dry
cough, dyspnoea functional class II, CRP level of 25 mg/l,
and lung function deterioration (Table 1). Furthermore, a
subcutaneous mass of the vertex had developed which, on
MRI, corresponded to a cranial bone tumour without
cerebral involvement. PET-scan showed diffuse lung hy-
permetabolism, with focal hypermetabolism of the cranial
bone mass (SUV max was 3.9). The tumour was removed
surgically. Histology disclosed a LCH bone lesion not
invading the meninges, with positive CD1a and S-100
staining. The patient received 3 additional courses of
intravenous cladribine with good tolerance. She was asym-
ptomatic at the end of treatment. PET-scan showed no
hypermetabolism. HRCT findings improved significantly.
CRP level was 4 mg/l. Disease remission persisted to the
last visit 4 years after the end of treatment.
Patient 3: A 55-year-old woman, smoker (40 pack-years),
presented with dyspnoea functional class II-III and chronic
cough. CRP level was elevated at 83 mg/l. Chest HRCT
showed a typical PLCH pattern, with numerous small nod-
ules and thick-walled cysts. Pulmonary function tests indi-
cated isolated reduction of DLco (72% of predicted), with
normal spirometry – FVC: 2.47 l (95%); FEV1: 1.96 l (89%);
FEV1:FVC: 75%; total lung capacity (TLC): 4.6 l (102%).
Echocardiography was normal. PET-scan demonstrated
diffuse lung hypermetabolism without extra-pulmonary
involvement (SUV max: 5.5). Despite smoking cessation,
FEV1 declined by 280 ml over 6 months of follow-up.
Right lung surgical biopsy confirmed the PLCH. The
patient then received 2 courses of subcutaneous cladribine,
in March and April 2013. In May 2013, however, she pre-
sented right pneumothorax needing chest tube drainage,
with recurrence in June 2013 requiring thoracic surgery
with pleurodesis. A third course of cladribine therapy was
administered in July 2013. In October 2013, she had
dyspnoea functional class I, without cough. CRP level was
3 mg/l. HRCT findings showed significantly decreased
nodules, with complete resolution of several thick-walled
cysts (Figure 2). PET-scan after treatment found no signifi-
cant hypermetabolism. Pulmonary function tests disclosed
improvement of FEV1 (+300 ml) and FVC (+420 ml), with
unchanged DLco.
Patient 4: A 50-year-old current smoker (40 pack-years)
was admitted in June 2011 for spontaneous left pneumo-
thorax, night sweats, and weight loss (−7 kg). His past
medical history included chronic obstructive pulmonary
disease (GOLD class III) with emphysema, treated with
inhaled tiotropium, budesonide and formeterol. Chest
HRCT revealed diffuse micronodules without cysts, and
“atypical emphysema”. PET-scan showed no pulmon-
ary hypermetabolism. Lung surgical biopsy demonstra-
ted PLCH, with involvement of the bronchioles, and
emphysematous changes. Echocardiography was normal.Although pneumothorax had resolved, dyspnoea func-
tional class II persisted, and pulmonary function tests
indicated an obstructive pattern. Despite complete smok-
ing cessation in March 2013, lung function continued to
deteriorate, with FEV1 decreasing by 200 ml and FVC by
100 ml over 6 months, and dyspnoea functional class II.
CRP level was 22 mg/l. Chest HRCT was unchanged.
Cladribine therapy was initiated. Seven days after the first
course, the patient presented infectious pneumonia, with-
out neutropenia, and was successfully treated with intra-
venous ceftriaxone, but required transfer to the intensive
care unit for 48 hours. The second course was compli-
cated by severe neutropenia (grade 4) on day 12, without
fever or infection. A 25% dose reduction of cladribine was
decided for the third course, which was well tolerated.
Cladribine therapy was followed by general improvement,
with unchanged dyspnoea functional class II. FVC and
FEV1 values increased by 130 ml and 200 ml, respectively.
CRP level was 7 mg/l. HRCT findings improved signifi-
cantly. PET-scan showed no hypermetabolism.
Patient 5: A 40-year-old woman, ex-smoker (20 pack-
years up to 3 years earlier), presented dyspnoea func-
tional class II-III in association with diabetes insipidus.
MRI showed isolated pituitary stalk enlargement. Hor-
monal analyses indicated isolated central diabetes insipi-
dus, which was treated with desmopressin. Chest HRCT
revealed thin-walled cysts and emphysematous-like lesions,
without nodules or thick-walled cysts. PET-scan showed
no significant hypermetabolism. Echocardiography was
normal. Lung functional tests disclosed a severely-
obstructive pattern: FVC: 2.6 l (80% of predicted),
FEV1: 0.8 l (29%), FEV1:FVC: 29%, TLC: 6.7 l (134%),
DLco: 30%. Αlpha-1 antitrypsin level, CRP and protein
electrophoresis were normal. A diagnosis of PLCH was
made. Treatment was attributed to long-term lung func-
tion decline despite smoking cessation and high-dose
inhaled bronchodilators, with a mean decrease of 300 ml/
year and 233 ml/year in FEV1 and FVC, respectively, over
a 3-year period. The patient received 4 courses of subcu-
taneous cladribine therapy, with good tolerance. No im-
provement was observed in dyspnoea, arterial blood gases,
and HRCT findings, but FEV1 recovered by 100 ml
(Table 1, Figure 1), and the FVC decline was stopped. The
patient was considered stable at the last visit, 2 years after
the last cladribine dose, and evaluation for lung trans-
plantation was postponed.
Discussion
We report on 5 patients successfully treated with cladri-
bine for progressive PLCH with obstructive ventilator pat-
tern. Cladribine treatment arrested the decline in FEV1
and was followed by either stabilization (patient 5) or im-
provement (patients 1 to 4) of airflow limitation. Although
additional evidence is needed through placebo-controlled
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bine, as a single agent, may be considered as rescue ther-
apy in subjects with severe disease worsening despite
smoking cessation and, in some cases, despite oral corti-
costeroids. All patients were younger than 55 years,
and at least 2 of them (patients 1 and 5), in whom
lung transplantation would have been considered over
the mid-term, were stabilised after cladribine therapy, and
transplantation was not deemed necessary.
The outcome of treatment may be more evident in
individuals with moderately severe obstructive lung dis-
ease due to PLCH and not confounded by tobacco smok-
ing, but disease stabilisation and some clinical benefits
were also observed in patients 4 and possibly 5 with severe
chronic obstructive ventilatory pattern related to both
PLCH and history of tobacco-smoking. BRAF V600E
mutation in 2 patients (2 and 4) did not seem to affect the
response to cladribine. Three of 5 patients (3, 4, and 5)
were treatment-naive, whereas cladribine was given after
unsuccessful first-line prednisolone therapy in the first 2
cases who had rapidly progressive PLCH despite smoking
cessation. Encouraging results in the first treated patients
led us to consider potential cladribine therapy earlier in
disease management of more recent cases. Given the
currently low level of evidence, we think that treat-
ment decisions should probably be based on the degree of
lung impairment and on the rapidity of disease worsening.
Interestingly, cladribine was successful in 1 patient with
relapsing pulmonary disease (patient 2).
Chest HRCT showed improvement in most cases, with
significantly decreased nodules and thick-walled cysts.
No significant change was observed in HRCT findings in
patient 5 with thin-walled cysts and emphysematous
alterations consistent with relatively-stable lung function
in this patient, likely corresponding to non-inflammatory
disease. The observation is consistent with a pathological-
radiological correlation study, suggesting that nodules on
imaging generally correspond to an active granulomatous
process at pathology, whereas cavitary lesions on imaging
usually reflect still active inflammatory cavitary granu-
lomas or cicatricial fibrous cysts [20]. Cladribine therapy
may, therefore, be particularly effective in PLCH subjects
with a predominant pattern of diffuse nodules and/or
thick-walled cysts on HRCT.
Hypermetabolism on PET-scan has been reported in
PLCH patients, with more frequent and higher metabol-
ism early in the course of the disease and in those with
nodular lung lesions as well as thick-walled cysts on chest
imaging [21]. In the present series, patients 2 and 3, who
had positive PET findings and predominantly diffuse
nodules as well as thick-walled cysts at HRCT, were also
those with the greatest improvement in lung function after
cladribine therapy. Whether PET may be undertaken to
identify patients with active nodular lung lesions andpredict better responses to cladribine therapy remains to
be investigated prospectively.
Cladribine further improved haemodynamics in 1 pa-
tient with severe PH associated with PLCH, consistent
with reports showing involvement of pulmonary arteries
and veins in granulomas and remodeled pulmonary arter-
ies within Langerhans cell granulomas [22,23], as also seen
in sarcoidosis.
Cladribine is a chemotherapeutic agent with potential
toxicity, including infections related to immunosuppres-
sion, cytopenia, vomiting, diarrhoea, increased liver en-
zymes, rash, purpura and, less frequently, neurotoxicity.
Treatment of our patients was remarkably uneventful,
with the notable exception of 1 patient (#4) who had
infectious pneumonia with bronchospasm successfully
controlled by antibiotic therapy. Later, the patient had
grade 4 neutrocytopenia without infection, which did
not relapse after dose adjustment. Patients systematically
received preventive therapy with oral trimethoprim/sul-
famethoxazole and valaciclovir, and were monitored for
cytopenia. The subcutaneous route was preferred to intra-
venous injection in most cases for convenience and good
tolerance.
Limitations of this study include small sample size
related to low PLCH prevalence with, furthermore, a
small proportion of patients incurring rapidly progres-
sive disease refractory to smoking cessation and/or corti-
costeroids. Although placebo-controlled randomised
trials would ideally be desirable for this condition, pa-
tient inclusion has recently proven to be challenging
(www.clinicaltrials.gov, NCT01473797), as those at risk
of progression to chronic respiratory insufficiency and
their doctors are understandably reluctant to partici-
pate. Despite the retrospective design, patients in our
study were monitored very closely, ensuring exhaus-
tive capture of adverse events and outcome variables.
Tolerance and safety were generally acceptable, with a
favourable benefit:risk ratio, but long-term follow-up
is warranted regarding potential secondary malignan-
cies that could be facilitated by cladribine. Tobacco-
smoking was a potentially-confusing factor in patient
3, who quit the habit between the second and third
courses of cladribine. Patients received 3 to 4 courses of
cladribine, but the optimal number of courses, and the po-
tential utility of maintenance therapy, need to be explored
further.
Conclusion
In conclusion, cladribine, as a single agent, may be effect-
ive therapy in PLCH patients. It may be considered, espe-
cially in subjects with progressive disease despite smoking
cessation, with nodular lung lesions and/or thick-walled
cysts on chest HRCT, and with diffuse hypermetabolism
of lung lesions on PET-scan.
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